NCT02739295View on ClinicalTrials.gov

G-CSF in the Treatment of Toxic Epidermal Necrolysis

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

March 7, 2023

Study Completion Date

March 7, 2023

Conditions
Stevens - Johnson Syndrome
Interventions
DRUG

recombinant granulocyte - colony stimulating factor

DRUG

NaCl 0.9%

Trial Locations (2)

4000

Burn Centre of the University Hospital of Liège, Liège

Unknown

IMTR Burn Centre, Loverval

All Listed Sponsors
lead

University of Liege

OTHER

NCT02739295 - G-CSF in the Treatment of Toxic Epidermal Necrolysis | Biotech Hunter | Biotech Hunter